2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2008

Assessing Treat To Target In Gout Patients With and Without Tophi
Abstract Number: 1974

Assessing Validity Of Low Field Magnetic Resonance Imaging (MRI) for Joint Inflammation and Damage In Wrist/Hand Rheumatoid Arthritis (RA) – A Systematic Literature Review (SLR)
Abstract Number: 961

Assessment and Promotion of a National Immunology Curriculum for Adult Rheumatology Residents
Abstract Number: 1649

Assessment Of Cytomegalovirus-Specific T Cell Responses Upon Initiation Of Immunosuppression In Patients Suffering From Rheumatic Diseases As Novel Approach For Functional Immune Monitoring
Abstract Number: 2123

Assessment Of Gesture Behavior and Knowledge On Low Back Pain Among Nurses
Abstract Number: 2279

Assessment Of Global Disease Activity In Rheumatoid Arthritis By Patients and Physicians: Cultural Differences Among Countries In The Meteor Database
Abstract Number: 2332

Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
Abstract Number: 1681

Assessment of Patients With Takayasu’s Arteritis in Routine Clinical Follow-Up With Indian Takayasu Clinical Activity Score 2010(ITAS2010)
Abstract Number: 276

Assessment Of Radiographic Progression In Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From The Tender Trial
Abstract Number: 2252

Assessment Of Rheumatoid Arthritis Disease Activity By Patients and Physicians: Do Physicians Detect Improvement Before The Patient Does?
Abstract Number: 1118

Assessment Of Structural Damage In Patients With Ankylosing Spondylitis Using 18F-Fluoride Positron Emission Tomography-Magnetic Resonance Imaging
Abstract Number: 2343

Assessment Of Subclinical Atherosclerosis (Flow Mediated Dilatation and arterial stiffness) After 24 Weeks Of a Tocilizumab Therapy In 22 Patients With Rheumatoid Arthritis
Abstract Number: 2274

Assessment Of The Diagnostic Accuracy Of Different Strategies For Health Fair Case-Finding For Undiagnosed Inflammatory Arthritis
Abstract Number: 690

Assessment Of The New American and European Classification Criteria For Systemic Sclerosis In The Norwegian Systemic Connective Tissue Disease and Vasculitis Registry
Abstract Number: 418

Assessment Of Treatment Effect Over Insulin Resistance and Adipokines In Patients With Early Rheumatoid Arthritis: A 6 Months Longitudinal Observational Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].